Literature DB >> 21248317

Multiple sclerosis prevalence in Ireland: relationship to vitamin D status and HLA genotype.

R Lonergan1, K Kinsella, P Fitzpatrick, J Brady, B Murray, C Dunne, R Hagan, M Duggan, S Jordan, M McKenna, M Hutchinson, N Tubridy.   

Abstract

BACKGROUND: The relationship between prevalence of multiple sclerosis (MS) and latitude may be due to both genetic and environmental factors. The hypothesis that, in Ireland, MS prevalence is increasing and that north-south differences relate to variation in serum 25-hydroxyvitamin D (25(OH)D) levels was tested in this study. PATIENTS AND METHODS: Patients and matched control subjects were identified in counties Donegal, Wexford and South Dublin through multiple sources. Prevalence was determined. Blood samples were taken for serum 25(OH)D and serum intact parathyroid hormone measurement, and DNA was extracted.
RESULTS: Prevalence in 2007 was significantly greater in Donegal (northwest) (290.3/105, 95% CI 262.3 to 321.7) compared with 2001 (184.6/105; 162 to 209.5). In Wexford (southeast), there was a non-significant increase in prevalence in 2007 compared with 2001. Prevalence was significantly higher in Donegal than in Wexford (144.8/105; 126.7 to 167.8, p<0.0001) and South Dublin (127.8/105; 111.3 to 148.2, p<0.0001). Overall, mean 25(OH)D levels were low and did not differ between patients (38.6 nmol/l) and controls (36.4 nmol/l) However, significantly more patients than controls had 25(OH)D levels <25 nmol/l (deficiency) (p=0.004). Levels of 25(OH)D (mean 50.74 nmol/l) were significantly higher in South Dublin (area with lowest prevalence) (p<0.0001) than in Donegal or Wexford. HLA DRB1*15 occurred most frequently in Donegal (greatest MS prevalence) and least frequently in South Dublin.
CONCLUSION: Vitamin D deficiency is common in Ireland. Latitudinal variation in MS probably relates to an interaction between genetic factors and environment (25(OH)D levels), and MS risk may be modified by vitamin D in genetically susceptible individuals.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248317     DOI: 10.1136/jnnp.2010.220988

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  14 in total

1.  Immunomodulators for multiple sclerosis may ameliorate spinal bone loss.

Authors:  M J McKenna; B Murray; R Lonergan; J M T Redmond
Journal:  Ir J Med Sci       Date:  2012-04-07       Impact factor: 1.568

2.  Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor.

Authors:  Yanping Wang; Steven J Marling; Jinge G Zhu; Kyle S Severson; Hector F DeLuca
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-16       Impact factor: 11.205

3.  Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study.

Authors:  Stine Marit Moen; Elisabeth Gulowsen Celius; Leiv Sandvik; Magritt Brustad; Lars Nordsletten; Erik Fink Eriksen; Trygve Holmøy
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

4.  Which clinical risk factors determine a pathological urodynamic evaluation in patients with multiple sclerosis? an analysis of 100 prospective cases.

Authors:  A Wiedemann; M Kaeder; W Greulich; H Lax; J Priebel; R Kirschner-Hermanns; I Füsgen
Journal:  World J Urol       Date:  2012-01-07       Impact factor: 4.226

5.  Contribution of GPR30 for 1,25 dihydroxyvitamin D₃ protection in EAE.

Authors:  Sandhya Subramanian; Lisa M Miller; Marjorie R Grafe; Arthur A Vandenbark; Halina Offner
Journal:  Metab Brain Dis       Date:  2011-10-13       Impact factor: 3.584

6.  Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Authors:  Charles Pierrot-Deseilligny; Jean-Claude Souberbielle
Journal:  Ther Adv Neurol Disord       Date:  2013-03       Impact factor: 6.570

7.  Limited utility of tartrate-resistant acid phosphatase isoform 5b in assessing response to therapy in osteoporosis.

Authors:  J J Brady; R K Crowley; B F Murray; M T Kilbane; M O'Keane; M J McKenna
Journal:  Ir J Med Sci       Date:  2013-06-05       Impact factor: 1.568

8.  What is needed to keep persons with multiple sclerosis vitamin D-sufficient throughout the year?

Authors:  Linn H Steffensen; Magritt Brustad; Margitta T Kampman
Journal:  J Neurol       Date:  2012-08-01       Impact factor: 4.849

9.  Incidence and prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General Practice Research Database.

Authors:  I S Mackenzie; S V Morant; G A Bloomfield; T M MacDonald; J O'Riordan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-09-19       Impact factor: 10.154

10.  Dose-related effects of vitamin D on immune responses in patients with clinically isolated syndrome and healthy control participants: study protocol for an exploratory randomized double- blind placebo-controlled trial.

Authors:  Karen O'Connell; Siobhan Kelly; Katie Kinsella; Sinead Jordan; Orla Kenny; David Murphy; Eric Heffernan; Risteard O'Laoide; Donal O'Shea; Carmel McKenna; Lorraine Cassidy; Jean Fletcher; Cathal Walsh; Jennifer Brady; Christopher McGuigan; Niall Tubridy; Michael Hutchinson
Journal:  Trials       Date:  2013-08-27       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.